American researchers discover a vaccine that may help ward off cervical cancer
One dose of Cervarix
could prevent as many cases of cervical cancer
as the current two- and three-dose schedules, a new study contends.
The vaccine protects against HPV types 16 and 18, which doctors believe cause about 70% of cervical cancers.
Doctors originally approved the vaccine to be given in three doses over six months, but many countries are switching to a two-dose schedule in teenagers. The US Centers for Disease Control and Prevention still recommends three doses for young Americans.
Researchers conducted two large phase 3 clinical trials that included more than 26,000 women between the ages of 15 and 25. They lived in North America, Latin America, Europe and Asia.
The researchers found that one dose of Cervarix offered similar levels of protection over four years when compared to two and three doses.
The findings were published online June 9 in The Lancet Oncology. Cervarix maker GlaxoSmithKline provided funding for one of the studies.
************ Best seller *************
The real key to healing cancer is to wipe out the stealth disease lurking behind it...
I admit I was downright shocked when I found out that cancer
isn't actually what kills most cancer patients! And I've been a doctor for well over 20 years - so not much surprises me anymore.
Even more astounding - this monumental discovery goes back to the 1970s when former US Air Force Dr Joseph Gold uncovered the REAL killer, a condition that no one in the medical field was even talking about!
That's right - the real culprit behind 3 out of every 4 cancer deaths isn't cancer at all. No! It's a syndrome you've probably never even heard of - called cachexia (pronounced "ka-kek-see-ah").
Cervarix could especially helpful in preventing cervical cancer in less developed regions of the world, where more than 80% of cases occur
“Our findings question the number of HPV vaccine doses truly needed to protect the majority of women against cervical cancer, and suggest that a one-dose schedule should be further evaluated,” co-study author Aimee Kreimer, of the US National Cancer Institute, said in a journal news release.
“If one dose is sufficient, it could reduce vaccination and administration costs, as well as improve uptake. This is especially important in less developed regions of the world where more than 80% of cervical cancer cases occur,” she explained.
However, further research is needed before vaccination guidelines can be changed, according to co-lead study author Cosette Wheeler, of the University of New Mexico Health Sciences Center in Albuquerque. She said researchers need to conduct trials lasting longer than four years to see how long the protection from one dose lasts.
But the idea of a one-dose vaccine is certainly a welcome one, experts said.
“If HPV vaccines could be delivered as one dose, while retaining their efficacy [effectiveness] against the most oncogenic HPV types 16 and 18, the global burden of cervical cancer would substantially decrease,” Dr. Julia Brotherton, of the Victorian Cytology Service Registries in Melbourne, Australia, said in the news release.
Are you ready to find out the root of all cancers? In the April 2015 issue of the Natural Health Dossier
, we let you in on this secret. To access this issue and others, join Natural Health Dossier today.
It’s quick and easy!